Characterization of the Sensory Nerve Action Potential of the Sural Nerve in Patients Over 60 Years of Age without Peripheral Neuropathy

Values and diagnostic accuracy of sensory nerve action potentials in control participants and participants with diabetes with and without clinical diabetic neuropathy, based on neuropathy scale measurements

“…Our data show that the ranges of sensory action potentials among patients with normal scores on neuropathy‐assessment scales are consistent with previously reported normal ranges (Esper et al., 2005 ; Geney‐Castro et al., 2022 ; Lo et al., 2006 ; Overbeek et al., 2005 ). Our data have the advantage of using validated neuropathy‐screening clinical tools to determine the presence or absence of neuropathy and show the merit of using prospectively collected data.…”

“…This could possibly be related to the use of standardized neuropathy scales in our study as a more robust method to differentiate between control participants and participants with clinical diabetic neuropathy. The sural nerve was measured in a cohort of 101 participants above the age of 60 years, with an average amplitude of 15 μV, which was higher than the average value observed in our control participants (7.5 μV), as well as in the participants with diabetes without neuropathy (6.6 μV) (Geney-Castro et al, 2022). Lo et al included 90 control participants and reported an average SPSA of 17.5 μV for participants aged 35-55 years and 6 μV for those above 55 years of age; this is higher than the median SPSA of 8 μV observed for the 40-59-year AG in our study, and rather similar to the median value for our >60 years AG (5 μV).…”

“…This could possibly be related to the use of standardized neuropathy scales in our study as a more robust method to differentiate between control participants and participants with clinical diabetic neuropathy. The sural nerve was measured in a cohort of 101 participants above the age of 60 years, with an average amplitude of 15 μV, which was higher than the average value observed in our control participants (7.5 μV), as well as in the participants with diabetes without neuropathy (6.6 μV) (Geney‐Castro et al., 2022 ). Lo et al.…”